Pre-earnings options volume in Eledon Pharmaceuticals (ELDN) is normal with calls leading puts 724:1. Implied volatility suggests the market is anticipating a move near 11.7%, or 34c, after results are released. Median move over the past eight quarters is 4.5%.
Claim 55% Off TipRanks
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Discover top-performing stock ideas and upgrade to a portfolio of market leaders with Smart Investor Picks
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on ELDN:
- Eledon Pharmaceuticals, Inc. (ELDN) Q4 Earnings Cheat Sheet
- Compelling Tegoprubart Data in Type 1 Diabetes Transplantation Support Buy Rating on Eledon
- Eledon announces updated data from islet transplant trial of tegoprubart
- Eledon Pharmaceuticals announces U.S. FDA granted ODD to tegoprubart
- NewcelX announces research agreement with Eledon Pharmaceuticals